Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2026-03-31 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Efzimfotase alfa Ph3 program show positive results
Regulatory Filings Classification · 1% confidence The document is an RNS regulatory announcement (“RNS Number: 7141Y”) by AstraZeneca disclosing positive Phase III clinical trial results for efzimfotase alfa. It is not a formal financial report (no financial statements or earnings metrics), nor a management presentation, dividend notice, M&A, or other specific category. It falls into the general regulatory announcements category for miscellaneous corporate updates delivered via the RNS service.
2026-03-31 English
6-K - ASTRAZENECA PLC (0000901832) (Filer)
Foreign Filer Report
2026-03-27 English
Tozorakimab met OBERON/TITANIA primary endpoints
Regulatory Filings Classification · 1% confidence The document is a Regulatory News Service (RNS) announcement from AstraZeneca PLC containing inside information about Phase III clinical trial results for tozorakimab. It is a substantive press release via the London Stock Exchange's RNS mechanism, not an earnings release, dividend notice, corporate action, or formal report publication announcement. It does not fit into any specific filing categories such as Annual Report, Interim Report, Earnings Release, or M&A. Therefore, it falls under the fallback category of Regulatory Filings (RNS).
2026-03-27 English
Tozorakimab met OBERON/TITANIA primary endpoints
Regulatory Filings Classification · 1% confidence The document is an RNS press release issued via the London Stock Exchange news service announcing clinical trial results for tozorakimab. It is not a financial report (10-K, IR, ER) nor a corporate governance, capital, M&A or dividend announcement. It is therefore best categorized under the fallback “Regulatory Filings” category (RNS).
2026-03-27 English
6-K - ASTRAZENECA PLC (0000901832) (Filer)
Foreign Filer Report
2026-03-20 English
Notification of Admission of Shares
Share Issue/Capital Change Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from AstraZeneca PLC regarding the admission of further securities to trading on the London Stock Exchange. It details the issuance of 45,750 new ordinary shares related to employee share schemes. This falls under the category of share issuance or capital changes, which is specifically covered by the 'SHA' (Share Issue/Capital Change) filing type.
2026-03-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.